Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Recent Earnings And Share Price Pressure

Simply Wall St.

02/28

Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2614896351"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614896351\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614896351?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-02-28 08:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614896351","market":"us","top_or_hot":-1,"title":"Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Recent Earnings And Share Price Pressure","media":"Simply Wall St.","content":"<div>\n<p>Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/assessing-grand-pharmaceutical-group-sehk512-valuation-after\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Recent Earnings And Share Price Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Grand Pharmaceutical Group (SEHK:512) Valuation After Recent Earnings And Share Price Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-28 08:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/assessing-grand-pharmaceutical-group-sehk512-valuation-after><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/assessing-grand-pharmaceutical-group-sehk512-valuation-after\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/assessing-grand-pharmaceutical-group-sehk512-valuation-after","article_id":"2614896351","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-512/grand-pharmaceutical-group-shares/news/assessing-grand-pharmaceutical-group-sehk512-valuation-after","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614896351","pubTimestamp":1772238787,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its diversified healthcare business is currently valued.\nSee our latest analysis for Grand Pharmaceutical Group.\nAt a share price of HK$7.83, Grand Pharmaceutical Group has seen short term share price pressure, with a 90 day share price return decline of 4.74%. However, its 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"在近期盈利和股价压力后评估远大医药集团（SEHK：512）的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9,"DCF":1},"content_text":"Grand Pharmaceutical Group (SEHK:512) has drawn investor attention after posting annual revenue of HK$11,704.979 million and net income of HK$2,079.449 million, putting fresh focus on how its diversified healthcare business is currently valued. See our latest analysis for Grand Pharmaceutical Group. At a share price of HK$7.83, Grand Pharmaceutical Group has seen short term share price pressure, with a 90 day share price return decline of 4.74%. However, its 1 year total shareholder return of 62.83% and 3 year total shareholder return of 95.29% indicate stronger longer term momentum. If Grand Pharmaceutical’s healthcare exposure has caught your interest, this could be a good moment to broaden your watchlist with 114 healthcare AI stocks surfaced by the Simply Wall St screener. Those returns and the current HK$7.83 share price sit alongside an indicated 65% intrinsic discount and a 48% gap to the analyst target. So is Grand Pharmaceutical still undervalued, or is the market already pricing in future growth? AdvertisementPrice to Earnings of 13.2x: Is it justified? On a P/E of 13.2x at a last close of HK$7.83, Grand Pharmaceutical Group screens as cheaper than some peers, even though it sits slightly above the Hong Kong pharmaceuticals average. P/E compares the current share price to earnings per share, so for a healthcare company like Grand Pharmaceutical it reflects how much investors are paying for each unit of current profit. With earnings forecast to grow 12.48% per year and revenue expected to grow 10% per year, the current P/E suggests the market is assigning a moderate price to those forecasts rather than paying up for rapid expansion. Relative comparisons add extra context. The stock is described as expensive against the Hong Kong pharmaceuticals industry average P/E of 13.1x, but as good value versus a peer average P/E of 23.3x and an estimated fair P/E of 20x that our models suggest the market could move towards if expectations align. That mix of signals leaves P/E as a useful checkpoint rather than a clear verdict on its own. Explore the SWS fair ratio for Grand Pharmaceutical Group Result: Price to Earnings of 13.2x (UNDERVALUED) However, there are still risks, including the 4.74% 90 day share price decline and the possibility that analyst and intrinsic value estimates prove too optimistic. Find out about the key risks to this Grand Pharmaceutical Group narrative. Another View Using Our DCF Model While the 13.2x P/E hints at moderate pricing, our DCF model indicates a wider gap, with Grand Pharmaceutical Group trading at HK$7.83 versus an estimated future cash flow value of HK$22.44. If that gap closes only part way, how much of the potential upside is already on your radar? Look into how the SWS DCF model arrives at its fair value. 512 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Grand Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 223 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps Curious whether the optimism in this story outweighs the concerns investors are flagging? Take a moment to review the numbers yourself, then weigh up the 3 key rewards and 1 important warning sign to see how the balance of risks and rewards looks to you. Looking for more investment ideas? If Grand Pharmaceutical is on your radar, do not stop there. Widening your opportunity set with a few focused stock lists can reveal options you might otherwise miss.  Target potential value by scanning 223 high quality undervalued stocks that pair solid fundamentals with pricing that our screener currently flags as relatively attractive. Prioritise resilience by reviewing 324 resilient stocks with low risk scores that score well on financial strength and business risk, so you are not relying on a single story. Get ahead of the crowd by checking our screener containing 566 high quality undiscovered gems, where strong underlying metrics meet relatively low market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}